On March 28, 2019 ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI;Nasdaq: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, reported its lead clinical candidate, EPI-7386, for metastatic castration-resistant prostate cancer has been selected for a poster presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") Annual Meeting 2019 to be held March 29 – April 3 at the Georgia World Congress Center in Atlanta, Georgia (Press release, ESSA, MAR 28, 2019, View Source [SID1234534726]). The poster will expand on the preclinical characterization of EPI-7386 alone and in combination with current anti-androgens, as well as provide further information on the aniten class in general.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title:
A new generation of N-terminal domain androgen receptor inhibitors, with improved pharmaceutical properties, in castration-resistant prostate cancer models.
Authors:
Ronan Le Moigne, Nasrin R. Mawji, Adriana Banuelos, Jun Wang, Kunzhong Jian, Raymond Andersen, Marianne D. Sadar, Han-Jie Zhou, Peter Virsik. ESSA Pharmaceuticals; BC Cancer, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada
Session:
Experimental and Molecular Therapeutics, Novel Targets & Pathways.
Date & Time:
Monday April 1, 2019 from 8:00am – 12:00pm
Location:
Georgia World Congress Center, Atlanta, Georgia, Exhibit Hall B
Poster Section:
14
Poster Board No:
7
Abstract No:
1292
ESSA also announced that two abstracts have been selected for poster presentations at AACR (Free AACR Whitepaper) from the laboratory of Dr. Marianne Sadar, Distinguished Scientist and Scientific Co-Founder of Essa, Michael Smith Genome Sciences Centre, BC Cancer Agency and Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia. The featured abstracts will explore the use of aniten compounds in prostate and breast cancer preclinical models.
Title:
Targeting androgen receptors and cyclin-dependent kinases 4 and 6 in breast cancer.
Authors:
Amy H. Tien, Nasrin R. Mawji, Jun Wang, Marianne D. Sadar. BC Cancer, Vancouver, BC, Canada
Session:
Endocrine-related Cancers.
Date & Time:
Monday April 1, 2019 from 8:00am – 12:00pm
Location:
Georgia World Congress Center, Atlanta, Georgia, Exhibit Hall B
Poster Section:
2
Poster Board No:
1
Abstract No:
1000
Title:
Combining all-trans retinoic acid therapy with androgen receptor N-terminal domain inhibitors for the treatment of castration-resistant prostate cancer.
Authors:
Jacky K. Leung, Marianne D. Sadar. BC Cancer, Vancouver, BC, Canada
Session:
Endocrine-related Cancers.
Date & Time:
Monday April 1, 2019 from 8:00am – 12:00pm
Location:
Georgia World Congress Center, Atlanta, Georgia, Exhibit Hall B
Poster Section:
2
Poster Board No:
24
Abstract No:
1023